FindTrial
Sign In

Afinitor 2.5 mg tablets

DRUG2 trials

Sponsors

Institut Gustave Roussy, Genentech Inc.

Conditions

ChildrenEstrogen Receptor (ER)-PositiveHER2-NegativeLocally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapyadolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

Phase 3

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
Active, not recruitingCTIS2023-506821-12-00
Genentech Inc.Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy
Start: 2023-10-12Target: 59Updated: 2025-12-17
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0
RecruitingCTIS2023-506027-29-00
Institut Gustave Roussyadolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive, Children
Start: 2014-10-01Target: 423Updated: 2026-01-21